Barclays Maintains an 'Overweight' on CVS Caremark (CVS); Positive on Shares After Mee ing
Tweet Send to a FriendGet Alerts CVS Hot Sheet
Price: $59.20 +1.49%
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade CVS Now!
Barclays maintains an 'Overweight' on CVS Caremark (NYSE: CVS) price target of $50.00.
Analyst, Meredith Adler, said, "Earlier this week we hosted CVS' CFO, Dave Denton and its SVP of Investor Relations, Nancy Christal, in meetings with European investors. Management re-iterated previous guidance that the dispute between Walgreen and Express Scripts would benefit 2Q results by $0.03-$0.04 but that 2H12 guidance includes no benefit, even though they seemed confident that much of the new business would be retained even if the dispute was resolved."
Alder sees CVS making progress on several fronts, and believes in the company's manangement, but she feels the current share price isn't reflecting the positive outlook.
For an analyst ratings summary and ratings history on CVS Caremark click here. For more ratings news on CVS Caremark click here.
Shares of CVS Caremark closed at $45.17 yesterday, with a 52 week range of $31.30-$46.22.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Meredith Adler, said, "Earlier this week we hosted CVS' CFO, Dave Denton and its SVP of Investor Relations, Nancy Christal, in meetings with European investors. Management re-iterated previous guidance that the dispute between Walgreen and Express Scripts would benefit 2Q results by $0.03-$0.04 but that 2H12 guidance includes no benefit, even though they seemed confident that much of the new business would be retained even if the dispute was resolved."
Alder sees CVS making progress on several fronts, and believes in the company's manangement, but she feels the current share price isn't reflecting the positive outlook.
For an analyst ratings summary and ratings history on CVS Caremark click here. For more ratings news on CVS Caremark click here.
Shares of CVS Caremark closed at $45.17 yesterday, with a 52 week range of $31.30-$46.22.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Bausch & Lomb near deal to sell to Valeant Pharmaceuticals (VRX) - WSJ
- UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
- CVS Caremark Supporting Tornado Relief Efforts in Oklahoma and Texas
Create E-mail Alert Related Categories
Analyst Comments, Mergers and AcquisitionsRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
